Subtype
Renal Cell Carcinoma
CI-CAN-00006578RCCExplore in graph →
376 active trials17 approved drugs60 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006578RCCExplore in graph →
Clinical trials
1,622 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (276)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00732914 | Sequential Study to Treat Renal Cell Carcinoma | completed | Phase 3 | 272 | Sponsor GmbHOTHER | 1 | Apr 23, 2014 | clinicaltrials |
| NCT01449825 | Hepatic Monitoring for Pazopanib | completed | — | 1 | GlaxoSmithKlineINDUSTRY | 0 | Apr 21, 2014 | clinicaltrials |
| NCT00586105 |
| completed |
| Phase 3 |
| 39 |
| BayerINDUSTRY |
| 2 |
| Apr 16, 2014 |
| clinicaltrials |
| NCT00353301 | Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma | completed | Phase 2 | 25 | University of Colorado, DenverOTHER | 1 | Apr 14, 2014 | clinicaltrials |
| NCT01243359 | Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies | completed | Phase 1 | 6 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2014 | clinicaltrials |
| NCT00356460 | Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma | completed | Phase 1 | 29 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00348699 | AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery | completed | Phase 1 | 68 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT01836406 | Effect of Ketorolac and Remote Ischemic Preconditioning on Renal Ischemia-reperfusion Injury in Patients Undergoing Partial Nephrectomy | completed | N/A | 16 | Yonsei UniversityOTHER | 1 | Feb 19, 2014 | clinicaltrials |
| NCT00891475 | Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients | completed | Phase 1 / Phase 2 | 114 | Kidney Cancer Research BureauOTHER | 1 | Feb 13, 2014 | clinicaltrials |
| NCT00073307 | Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer | completed | Phase 3 | 903 | BayerINDUSTRY | 19 | Feb 6, 2014 | clinicaltrials |
| NCT00980213 | Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland | completed | — | 80 | Pirkko-Liisa Kellokumpu-LehtinenOTHER | 1 | Feb 6, 2014 | clinicaltrials |
| NCT02056587 | Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment | completed | Phase 4 | 37 | Kidney Cancer Research BureauOTHER | 1 | Feb 6, 2014 | clinicaltrials |
| NCT00387764 | Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer | completed | Phase 3 | 80 | GlaxoSmithKlineINDUSTRY | 20 | Jan 14, 2014 | clinicaltrials |
| NCT00718367 | Correlation of the Clinical Behaviour of Renal Cell Carcinoma (RCC) After Debulking Nephrectomy With Tumor Gene Expression in Nephrectomy Specimens | completed | — | — | National University Hospital, SingaporeOTHER | 1 | Jan 14, 2014 | clinicaltrials |
| NCT00836745 | Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent | completed | — | 36 | PfizerINDUSTRY | 1 | Dec 20, 2013 | clinicaltrials |
| NCT00586495 | Long-term Extension From RCC Phase II (11515) | completed | Phase 2 | 95 | BayerINDUSTRY | 1 | Dec 13, 2013 | clinicaltrials |
| NCT00602862 | Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250 | completed | N/A | 26 | Radboud University Medical CenterOTHER | 1 | Dec 2, 2013 | clinicaltrials |
| NCT00474786 | Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib(INTORSECT) | completed | Phase 3 | 512 | PfizerINDUSTRY | 20 | Nov 21, 2013 | clinicaltrials |
| NCT00876382 | Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma | completed | — | 47 | SCRI Development Innovations, LLCOTHER | 1 | Nov 14, 2013 | clinicaltrials |
| NCT01100619 | A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors | completed | Phase 1 | 40 | ExelixisINDUSTRY | 1 | Sep 19, 2013 | clinicaltrials |
| NCT00059813 | Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00678119 | Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment | completed | Phase 2 | 25 | Argos TherapeuticsINDUSTRY | 2 | Jul 15, 2013 | clinicaltrials |
| NCT01079286 | Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers(I-NET) | completed | Phase 1 | 18 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jul 15, 2013 | clinicaltrials |
| NCT00502034 | Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma. | completed | Phase 3 | 310 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00635791 | Phase I Study of Vorinostat and Sorafenib in Advanced Cancer | completed | Phase 1 | 36 | University of Colorado, DenverOTHER | 1 | Jun 20, 2013 | clinicaltrials |
| NCT00091182 | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | completed | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00354250 | Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00944905 | Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) | completed | Phase 1 | 46 | Bristol-Myers SquibbINDUSTRY | 1 | May 22, 2013 | clinicaltrials |
| NCT00425035 | Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2 | completed | Phase 2 | 115 | AmgenINDUSTRY | 0 | May 13, 2013 | clinicaltrials |
| NCT01381601 | Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics) | completed | — | 1 | GlaxoSmithKlineINDUSTRY | 0 | May 13, 2013 | clinicaltrials |
| NCT01381614 | Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS) | completed | — | 1 | GlaxoSmithKlineINDUSTRY | 0 | May 13, 2013 | clinicaltrials |
| NCT00112476 | Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00217542 | Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00089362 | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00182702 | Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2013 | clinicaltrials |
| NCT00494091 | Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 82 | PfizerINDUSTRY | 3 | Mar 21, 2013 | clinicaltrials |
| NCT00490698 | Zoledronate With Atorvastatin in Renal Cell Carcinoma | completed | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2013 | clinicaltrials |
| NCT01441661 | Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma | completed | — | 400 | Cancer Foundation, ChinaOTHER | 1 | Mar 18, 2013 | clinicaltrials |
| NCT00272649 | Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer | completed | Phase 1 / Phase 2 | 22 | Argos TherapeuticsINDUSTRY | 2 | Mar 14, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00060307 | Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00101114 | Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00087984 | RNA-Loaded Dendritic Cell Cancer Vaccine | completed | Phase 1 / Phase 2 | 26 | Argos TherapeuticsINDUSTRY | 2 | Feb 18, 2013 | clinicaltrials |
| NCT00619268 | Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma(TORAVA) | completed | Phase 2 | 160 | Centre Leon BerardOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00557609 | Phase 2 Study in Patients With MiT Tumors | completed | Phase 2 | 47 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 3 | Feb 8, 2013 | clinicaltrials |
| NCT00193258 | Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 94 | SCRI Development Innovations, LLCOTHER | 0 | Jan 31, 2013 | clinicaltrials |
| NCT00032188 | Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00706706 | Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma(MRCC RCC) | completed | Phase 4 | 105 | PfizerINDUSTRY | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00006486 | Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 335 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Apr 23, 2014source: clinicaltrials